12.79
+0.79
+(6.58%)
At close: February 18 at 4:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
Operating Cash Flow
77,763.00
-86,827.00
-99,203.00
Investing Cash Flow
-576.00
-441.00
-3,170.00
Financing Cash Flow
38,773.00
16,385.00
1,728.00
End Cash Position
150,695.00
30,246.00
101,129.00
Capital Expenditure
-576.00
-441.00
-1,966.00
Issuance of Capital Stock
--
--
1,574.00
Issuance of Debt
40,651.00
16,176.00
--
Free Cash Flow
77,187.00
-87,268.00
-101,169.00
12/31/2022 - 1/31/2025
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MTSR Metsera, Inc.
32.08
+4.91%
SION Sionna Therapeutics, Inc.
20.04
+0.05%
ALMS Alumis Inc.
5.06
-2.88%
SEPN Septerna, Inc.
6.87
-46.99%
AARD Aardvark Therapeutics, Inc. Common Stock
13.56
+1.95%
AAPG Ascentage Pharma Group Internat
18.51
+1.48%
BCAX Bicara Therapeutics Inc.
13.09
-2.89%
UPB Upstream Bio, Inc.
8.40
+10.53%
RAPP Rapport Therapeutics, Inc.
14.04
-11.70%
MBX MBX Biosciences, Inc.
10.90
+4.71%